Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1631 1632 1635 1699
This examiner grants 59% of resolved cases
Jianjian Zhu is in Tech Center 1600 and Art Unit 1631, with 85 resolved cases. The allowance rate is 58.8 percent. This 58.8 percent rate provides a baseline for understanding the examiner's tendencies in this art unit. Although the 85 cases represent a smaller dataset, they offer a clear indication of the examiner's approach to patent applications in Tech Center 1600.
The interview lift is remarkably high at 82.4 percent. This 82.4 percent lift suggests that interviews are an extremely powerful tool for moving cases toward allowance with this examiner. The median days to allowance is 1348 days. Given the baseline allowance rate, the lift is a critical metric for practitioners. The 1348 days median timeline can be navigated more effectively by prioritizing direct communication. These figures highlight the significant impact that oral advocacy can have on the outcome of the cases typically reviewed in Art Unit 1631.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18947127 | CELL CULTURE MEMBRANE AND ORGAN IMITATION STRUCTURE | Non-Final OA | TOYODA GOSEI CO., LTD. |
| 18026474 | CELL SUPPORT AND METHOD OF PRODUCING SAME, CELL CULTURE METHOD AND CELL STRUCTURE | Final Rejection | Konica Minolta, Inc. |
| 18978181 | FOAMY VIRUSES AND METHODS OF USE | Non-Final OA | Mayo Foundation for Medical Education and Research |
| 17495597 | MULTICELL CONJUGATES FOR ACTIVATING ANTIGEN-SPECIFIC T CELL RESPONSES | Final Rejection | Wisconsin Alumni Research Foundation |
| 18416749 | METHODS FOR SCREENING GENETIC PERTURBATIONS | Final Rejection | The Regents of the University of California |
| 17549028 | PHYSIOLOGIC GROWTH OF CULTURED INTESTINAL TISSUE | Non-Final OA | The Regents of the University of Michigan |
| 18696014 | TREATMENT OF POLYCYTHEMIA VERA VIA CRISPR/AAV6 GENOME EDITING | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17786359 | GENETICALLY CORRECTED CELLS FOR THERAPEUTIC USE | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 17168988 | ARRDC1-MEDIATED MICROVESICLES (ARMMS) AND USES THEREOF | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 17786255 | CHIMERIC ANTIGEN RECEPTOR DENDRITIC CELLS (CAR-DCS) AND METHODS OF MAKING AND USING SAME | Final Rejection | Washington University |
| 17436131 | TARGETED DELIVERY OF IMMUNE-MODULATING VHH AND VHH-FUSION PROTEIN | Non-Final OA | Massachusetts Institute of Technology |
| 19353269 | SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE | Non-Final OA | Allogene Therapeutics, Inc. |
| 17841041 | SELECTIVE TARGETING OF HOST CD70+ ALLOREACTIVE CELLS TO PROLONG ALLOGENEIC CAR T CELL PERSISTENCE | Final Rejection | Allogene Therapeutics, Inc. |
| 18035277 | CELLS EXPRESSING A CHIMERIC RECEPTOR FROM A MODIFIED INVARIANT CD3 IMMUNOGLOBULIN SUPERFAMILY CHAIN LOCUS AND RELATED POLYNUCLEOTIDES AND METHODS | Non-Final OA | Juno Therapeutics, Inc. |
| 18941862 | BIOACTIVE AND ANTIOXIDANT SUPRAMOLECULAR POLYMER HYDROGELS FOR NEURAL CELL CULTURE | Non-Final OA | Northwestern University |
| 18929526 | COST EFFECTIVE CULTURE MEDIA AND PROTOCOL FOR HUMAN INDUCED PLURIPOTENT STEM CELLS | Non-Final OA | Northwestern University |
| 17669904 | DIAGNOSIS AND TREATMENT OF CARDIOMYOPATHY | Non-Final OA | The General Hospital Corporation |
| 17511187 | CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF | Final Rejection | RESEARCH INSTITUTE AT NATIONWIDE CHILDREN'S HOSPITAL |
| 16960445 | 3D in vitro Models of Lung Tissue | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE |
| 17770585 | ENGINEERED NATURAL KILLER CELLS AND METHODS FOR USING THE SAME IN IMMUNOTHERAPY AND AUTOPHAGY INHIBITON TECHNIQUES | Final Rejection | Purdue Research Foundation |
| 18716889 | METHODS OF GENERATING HUMAN COCHLEAR HAIR CELLS | Non-Final OA | THE TRUSTEES OF INDIANA UNIVERSITY |
| 17709565 | NERVE CELL AND APPLICATION THEREOF | Final Rejection | KEIO UNIVERSITY |
| 17773103 | METHOD FOR THE PRODUCTION OF MÜLLER CELLS AND CELL PRODUCT | Non-Final OA | UCL BUSINESS LTD |
| 17997731 | PROCESSES FOR PRODUCTION OF TUMOR INFILTRATING LYMPHOCYTES AND USES OF THE SAME IN IMMUNOTHERAPY | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 17778611 | T-CELL MASTER CELL BANK | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18188795 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF | Non-Final OA | MEMORIAL SLOAN-KETTERING CANCER CENTER |
| 17606489 | ARTIFICIAL ANTIGEN PRESENTING CELLS COMPRISING LIGANDS FOR NKG2D FOR EXPANDING IMMUNE CELLS FOR IMMUNOTHERAPY | Final Rejection | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. |
| 17598916 | METHOD FOR PRODUCING CAR GENE-INTRODUCED NK CELLS AND USE THEREOF | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 18834112 | Methods for Activation and Expansion of T Cells | Non-Final OA | Alaunos Therapeutics, Inc. |
| 18547827 | Recombinant Vectors Comprising Polycistronic Expression Cassettes and Methods of Use Thereof | Non-Final OA | Alaunos Therapeutics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy